Article information
Full text is only aviable in PDF
References
[1]
Miravitlles M, Murio C, Guerrero T, Gisbert R.
Costs of chronic bronchitis and COPD. A one year follow-up study.
Chest, 123 (2003), pp. 784-791
[2]
Izquierdo Alonso JL, de Miguel Díez J.
Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease.
Journal of COPD, 1 (2004), pp. 215-233
[3]
Hilleman DE, Dewan N, Malesker M, Friedman M.
Pharmacoeconomic evaluation of COPD.
Chest, 118 (2000), pp. 1278-1285
[4]
Dahl R, Lofdahl CG.
The economic impact of COPD in North America and Europe. Analysis of the Confronting COPD survey.
Respir Med, 97 (2003), pp. 1-2
[5]
Rodríguez-Roisin R, Álvarez-Sala JL, Sobradillo V.
2002: un buen año capicúa para la EPOC.
Arch Bronconeumol, 38 (2002), pp. 503-505
[6]
Celli BR.
The importance of spirometry in COPD and asthma: effect on approach to management.
Chest, 117 (2000), pp. 15-19
[7]
Barberà JA, Peces-Barba G, Agustí AGN, Izquierdo JL, Monsó E, Montemayor T, et al.
Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 37 (2001), pp. 297-316
[8]
Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al.
Optimal assessment and management of chronic obstructive pulmonary disease (COPD).
Eur Respir J, 8 (1995), pp. 1398-1420
[9]
Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary.
Am J Respir Crit Care Med, 163 (2001), pp. 1256-1276
[10]
Ferguson GT, Enright PL, Buist AS, Higgins MW.
Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program.
Chest, 45 (2000), pp. 1146-1161
[11]
Sobradillo Peña V, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, et al.
Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study.
Chest, 118 (2000), pp. 981
[12]
Coultas DB, Mapel D, Gagnon R, Lydick E.
The health impact of undiagnosed airflow obstruction in a national sample of United States adults.
Am J Respir Crit Care Med, 164 (2001), pp. 372-377
[13]
Hueto J, Cebollero P, Pascal I, Cascante JA, Eguía VM, Teruel F, et al.
La espirometría en atención primaria en Navarra.
Arch Bronconeumol, 42 (2006), pp. 325-330
[14]
Giner J, Casan P, Berrogalviz MA, Burgos F, Macian V, Sanchis J.
Cumplimiento de las “recomendaciones SEPAR” sobre la espirometría.
Arch Bronconeumol, 32 (1996), pp. 516-522
[15]
de Miguel Díez J, Izquierdo Alonso JL, Molina Paris J, Rodríguez González-Moro JM, De Lucas Ramos P, Gaspar Alonso-Vega G.
Fiabilidad del diagnóstico de la EPOC en la atención primaria y neumología en España. Factores predictivos.
Arch Bronconeumol, 39 (2003), pp. 203-208
[16]
American Thoracic Society.
Standardization of spirometry: 1994 update.
Am J Crit Care Med, 152 (1995), pp. 1107-1136
[17]
Eaton T, Withy S, Garrett JE, Mercer J, Whitlock RM, Rea HH.
Spirometry in primary care practice. The importance of quality assurance and the impact of spirometry workshops.
Chest, 116 (1999), pp. 416-423
[18]
López de Santa María E, Gutiérrez L, Legorburu C, Valero M, Zabala M, Sobradillo V, Galdiz JB.
Calidad de la espirometría en las consultas neumológicas de un área jerarquizada.
Arch Bronconeumol, 38 (2002), pp. 204-208
[19]
Pérez-Padilla R, Valdivia G, Muiño A, López MV, Márquez MN, Montes de Oca M, et al.
Valores de referencia espirométrica en 5 grandes ciudades de Latinoamérica para sujetos de 40 o más años de edad.
Arch Bronconeumol, 42 (2006), pp. 317-324
[20]
Menezes AM, Pérez-Padilla R, Jardim JR, Muino A, López MV, Valdivia G, PLATINO Team, et al.
Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study.
Lancet, 366 (2005), pp. 1875-1881
[21]
Hankinson JL, Odencrantz JR, Fedan KB.
Spirometric reference values from a sample of the general U.S. population.
Am J Respir Crit Care Med, 159 (1999), pp. 179-187
[23]
Crapo RO, Morris AH, Gardner RM.
Reference spirometric values using techniques and equipment that meet ATS recommendations.
Am Rev Respir Dis, 123 (1981), pp. 659-664
[24]
Enright PL, Adams AB, Boyle PJ, Sherrill DL.
Spirometry and maximal respiratory pressure references from healthy Minnesota 65- to 85-year-old women and men.
Chest, 108 (1995), pp. 663-669
[25]
Quanjer PH.
Standardized lung function testing.
Bull Eur Physiopathol Respir, 19 (1983), pp. 1-95
[26]
Knudson RJ, Lebowitz MB, Holberg CJ, Burrows B.
Changes in the normal maximal expiratory flow-volume curve with growth and aging.
Am Rev Respir Dis, 127 (1983), pp. 725-734
[27]
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al.
Interpretative strategies for lung function tests.
Eur Respir J, 26 (2005), pp. 948-968
[28]
Enright PL, Beck KC, Sherrill DL.
Repeatability of spirometry in 18 000 adult patients.
Am J Respir Crit Care Med, 169 (2004), pp. 235-238
[29]
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.
Standardisation of spirometry.
Eur Respir J, 26 (2005), pp. 319-338
[30]
PLATINO-ALAT.
[31]
Finkelstein J, Cabrera M, Hripcsak G.
Internet-based home asthma telemonitoring. Can patients handle the technology?.
Chest, 117 (2000), pp. 148-155
[32]
Morlion B, Knoop C, Pavia M, Estenne M.
Internet-based home monitoring of pulmonary function after lung transplantation.
Am J Respir Crit Care Med, 165 (2002), pp. 694-697
[33]
Burgos F, Gistau C, Serrano T, García L, Brunet G, Hernández C, et al.
Reliability of forced spirometry in primary care (PC): assessment of the impact of a remote assistance program.
Proceedings of the American Thoracic Society, V2 (2005), pp. A35
[34]
Unifying efforts in the global fight against lung disease-.
Study partly supported by Red Respira ISC III (RTIC-03/11), Fondo de Investigación Sanitaria (FIS 042728), and MAPFRE 2006.
Copyright © 2006. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
